Literature DB >> 30038441

RxLegal: A Rapid Review of Right-To-Try.

Michael Gabay1.   

Abstract

Right-to-try legislation is intended to allow patients with life-threatening illnesses access to investigational medical treatments without formal Food and Drug Administration (FDA) involvement. Currently, right-to-try laws have been enacted in 40 states. Despite the increased passage of right-to-try legislation at the state level, individuals have detailed arguments both for and against these laws. Proponents state that right-to-try removes regulatory burdens and improves timely access to potentially lifesaving medications for terminally ill patients, reduces inequalities regarding access, and improves patient-provider communication and decision making. Opponents argue that right-to-try does not really guarantee access, reinforces preexisting health care inequalities, prioritizes rapid access over safety and the interests of the individual over the public, and produces concerns regarding informed consent. Despite these issues, right-to-try has recently gained traction on the federal level with both Congressional chambers passing separate bills.

Entities:  

Keywords:  ethics; investigational drugs; legal aspects

Year:  2018        PMID: 30038441      PMCID: PMC6050876          DOI: 10.1177/0018578718783992

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN: 0018-5787


  7 in total

1.  Right-to-try laws and individual patient "compassionate use" of experimental oncology medications: A call for improved provider-patient communication.

Authors:  Michael Hoerger
Journal:  Death Stud       Date:  2015-08-27

2.  Medical Negligence Determinations, the "Right to Try," and Expanded Access to Innovative Treatments.

Authors:  Denise Meyerson
Journal:  J Bioeth Inq       Date:  2017-06-20       Impact factor: 1.352

3.  Informed Consent in Right-To-Try Cases.

Authors:  Jennifer Piel
Journal:  J Am Acad Psychiatry Law       Date:  2016-09

Review 4.  The ethical plausibility of the 'Right To Try' laws.

Authors:  D Carrieri; F A Peccatori; G Boniolo
Journal:  Crit Rev Oncol Hematol       Date:  2017-12-24       Impact factor: 6.312

5.  The Federal Right to Try Act of 2017-A Wrong Turn for Access to Investigational Drugs and the Path Forward.

Authors:  Alison Bateman-House; Christopher T Robertson
Journal:  JAMA Intern Med       Date:  2018-03-01       Impact factor: 21.873

6.  Federal Right-to-Try Legislation - Threatening the FDA's Public Health Mission.

Authors:  Steven Joffe; Holly Fernandez Lynch
Journal:  N Engl J Med       Date:  2018-01-10       Impact factor: 91.245

7.  What is safety?: Miracles, benefit-risk assessments, and the "right to try".

Authors:  Lisa M DeTora
Journal:  Int J Clin Pract       Date:  2017-06-08       Impact factor: 2.503

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.